Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.
Int J Clin Oncol. 2019 Jun;24(6):712-720. doi: 10.1007/s10147-019-01404-2. Epub 2019 Feb 12.
To evaluate the efficacy and prognosis of repeated treatment on patients with recurrent endometrial cancer (EC) after complete remission for primary fertility-preserving therapy.
We performed a retrospective study of patients with presumed stage IA endometrial cancer who had recurrence after achieving complete remission by fertility-preserving management at the Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, from January 2003 to April 2018. For each patient, medical records and pathology reports were reviewed. The demographic features, treatment efficacy, tumor prognosis, and reproductive outcome were analyzed.
Of the 41 recurrent patients with a median disease-free interval period of 16 months (range, 5-55 months), 23 were diagnosed at recurrence as EC, and 18 were diagnosed as atypical hyperplasia (AH) or endometrial intraepithelial neoplasia (EIN). 26 patients received repeated fertility-preserving treatment, and 23 patients were evaluable for efficacy. The complete response (CR) rate of repeated treatment (19/23, 82.6%) was lower than that of primary fertility-preserving treatment (161/170, 94.7%) with borderline significance (P = 0.053). The CR rate of AH/EIN patients was higher than that of EC patients with no statistical difference (92.9% vs 66.7%, P = 0.260). Among 19 patients achieved CR, 3 got pregnant and delivered successfully, while 3 had a second relapse. Four cases failed to response to the repeated treatment and underwent definitive surgery. 15 patients referred to definitive surgery directly after recurrence and one of them had a pelvic recurrence after 120 months. All patients are alive without evidence of disease at last follow-up.
For patients with recurrent EC after primary fertility-preserving treatment, repeated fertility-preserving treatment can still achieve a promising response and patients have possibilities of completing childbirth.
评估对接受保留生育功能治疗后完全缓解的复发性子宫内膜癌(EC)患者进行重复治疗的疗效和预后。
我们对 2003 年 1 月至 2018 年 4 月期间,北京协和医院妇产科接受保留生育功能管理后完全缓解但复发的疑似 IA 期子宫内膜癌患者进行了回顾性研究。对每位患者的病历和病理报告进行了回顾。分析了患者的人口统计学特征、治疗效果、肿瘤预后和生殖结局。
41 例复发患者的无病间期中位数为 16 个月(范围,5-55 个月),其中 23 例复发时诊断为 EC,18 例诊断为不典型增生(AH)或子宫内膜上皮内瘤变(EIN)。26 例患者接受了重复的保留生育功能治疗,其中 23 例可评估疗效。重复治疗的完全缓解(CR)率(19/23,82.6%)低于初次保留生育功能治疗(161/170,94.7%),但差异无统计学意义(P=0.053)。AH/EIN 患者的 CR 率高于 EC 患者,但差异无统计学意义(92.9%比 66.7%,P=0.260)。在 19 例获得 CR 的患者中,有 3 例成功怀孕并分娩,3 例复发。4 例患者对重复治疗无反应,行根治性手术。15 例患者在复发后直接行根治性手术,其中 1 例在 120 个月后出现盆腔复发。所有患者末次随访时均存活,无疾病证据。
对于初次保留生育功能治疗后复发的 EC 患者,重复保留生育功能治疗仍能获得良好的疗效,患者有完成生育的可能。